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http:WHAT THIS PAPER ADDS
This article describes the ﬁrst comprehensive systematic review of structured, home-based exercise programmes
(HEPs) for individuals with intermittent claudication. There is “low-level” evidence that HEPs can improve
walking capacity and quality of life in patients with intermittent claudication, albeit probably to a lesser extent
than supervised exercise training.We recommend that HEPs should be used to promote walking in patients with
intermittent claudication when supervised training is unavailable or impractical. Further research is warranted to
establish long-term clinical and cost effectiveness, and optimal programme design.We aimed to conduct a systematic review of the evidence for structured, home-based exercise programmes
(HEPs) in patients with intermittent claudication. The Medline, PsycINFO, EMBASE, and Cochrane databases were
searched up to April 2013 for terms related to walking, self-management, and intermittent claudication.
Descriptive, methodological and outcome data were extracted from eligible articles. Trial quality was assessed
using the GRADE system. Seventeen studies were included with 1,457 participants. Six studies compared HEPs
with supervised exercise training, ﬁve compared HEPs with usual care/observation control, and seven evaluated
HEPs in a single-group design. Trial heterogeneity prevented meta-analysis. Nevertheless, there was “low-level”
evidence that HEPs can improve walking capacity and quality of life in patients with intermittent claudication
when compared with baseline or in comparison to usual care/observation control. In addition, improvements
with HEPs may be inferior to those evoked by supervised exercise training. Considerable uncertainty exists
regarding the long-term clinical and cost effectiveness of HEPs in patients with intermittent claudication. Thus,
more robust trials are needed to build evidence about these interventions. Nevertheless, clinicians should
consider using structured interventions to promote self-managed walking in patients with intermittent
claudication, as opposed to simple “go home and walk” advice, when supervised exercise training is unavailable
or impractical.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Peripheral arterial disease (PAD) is a chronic atherosclerotic
cardiovascular disease in which stenoses and/or occlusions
of the peripheral arteries limit blood ﬂow to the legs. The
age-adjusted prevalence is approximately 10%, increasing to
20% in individuals aged >70 years.1,2 The classic symptom
of mild-to-moderate PAD is intermittent claudication (IC),
which is lower limb pain or discomfort that is induced byTo access continuing medical education questions on this pa-
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//dx.doi.org/10.1016/j.ejvs.2013.09.004walking and relieved by rest. IC decreases functional ca-
pacity and quality of life,3 and is associated with an
increased risk of cardiovascular morbidity and mortality.4
A primary treatment option for patients with IC is a
programme of supervised walking exercise, typically deliv-
ered as a 3-month programme in a hospital or healthcare
clinic.2,5 Medically-supervised exercise programmes have
demonstrated clinical efﬁcacy with large improvements
noted for pain-free and maximum walking distances/
times.6,7 Improvements in patient-reported outcomes and
measures of cardiovascular health have also been re-
ported.8,9 Despite this evidence and the current recom-
mendations, supervised exercise programmes are largely
under-utilised,10 possibly owing to lack of reimbursement
from insurance companies, the likelihood that only a small
proportion of patients would be able to attend regularly,
and concerns regarding long-term cost-effectiveness. As a
result, exercise is most commonly promoted in the form of
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“usual care” have often served as the control group in
clinical trials, and research suggests this approach is inef-
fective.11,12 This has prompted increased interest in the
development of structured interventions that promote self-
managed walking in the community (home-based exercise
programmes [HEPs]). However, the role of HEPs in the
management of PAD/IC is currently unclear. To inform the
development of a coherent evidence-base with which to
direct future research and disease-management policy we
conducted a systematic review of HEPs in patients with IC.Figure 1. Study selection. Note. * The total number of studies is 17
because the study of Gardner et al.9 was a three-arm randomised
controlled trial of a home-based exercise programme (HEP) versus
supervised exercise programme versus usual care.MATERIALS AND METHODS
The Medline, PsycINFO, EMBASE, and Cochrane databases
were systematically searched by two independent re-
viewers (WA, GT) for studies evaluating the effects of HEPs
in patients with IC. Search terms included “peripheral
arterial disease”, “self-management”, “exercise”, and
“walking”. There were no date restrictions and only English-
language articles were considered. Studies were also iden-
tiﬁed through checking reference lists of related papers. The
search ended in April 2013.
We retrieved and analysed clinical trials that reported
results of the effect of HEPs with or without comparisons
with other exercise strategies, such as supervised exercise
training and basic walking advice (usual care). Studies of
asymptomatic patients or those with atypical symptoms
were excluded. We included both randomised and non-
randomised prospective and retrospective studies.
Information about study design, participant characteris-
tics, intervention components, outcome measures, and
ﬁndings were extracted by WA and GT. The primary
outcome of interest was objectively-measured maximum
walking distance (MWD) or time (MWT). Where possible,
effect sizes (ES) were calculated for MWD/MWT using the
methods of Morris13 for differences in changes between
groups (ESBG) and Cohen
14 for within-group changes from
baseline (ESWG), with 0.2, 0.5, and 0.8 representing small,
moderate, and large ES respectively. In studies with >1
follow-up assessment, data from the ﬁnal assessments were
used to calculate ES. Secondary outcome measures were
pain-free walking distance (PWD) or time (PWT), self-
reported functional status and health-related quality of
life, and cardiovascular risk markers.
Study quality was assessed by WA, GT, and KM using the
GRADE system.15 Here, each study was initially assigned a
quality rating based on the study design: “high” for rand-
omised controlled trials (RCTs) and “low” for observational
studies. The rating was then downgraded for the following
criteria: study limitations (risk of bias), inconsistency, indi-
rectness, and imprecision, which are described elsewhere.15
Decisions on precision were based on a minimum important
difference equalling an effect size of 0.33. Observational
studies were upgraded if there was a large magnitude of
effect, doseeresponse gradient, and if all plausible con-
founding would reduce a demonstrated effect or suggest a
spurious effect when results showed no effect. Each qualityelement considered to have “serious” or “very serious”
problems was rated down e1 or e2 points respectively. The
downgraded/upgraded marks were then summed and the
overall quality rating was revised, with studies categorised
as high (further research is unlikely to change our conﬁ-
dence in the estimate of effect), moderate, or low (any
estimate of effect is uncertain).
RESULTS
Study inclusion and characteristics
The search identiﬁed 311 articles (Fig. 1), of which 18 articles
reporting 17 studies were accepted. Six studies compared a
HEP with supervised exercise training (Table 1),9,16e20 and
ﬁve compared a HEP with usual care or observation control
(Table 2).8,9,12,21e23 The study of Gardner et al.9 was a three-
arm randomised trial of HEP versus supervised exercise
training versus usual care. Seven studies evaluated HEPs in a
single-group design (Table 3).24e30 Quality assessment pro-
ﬁles are presented in Table 4. The total number of partici-
pants was 1,457, ranging from 1421 to 25030 for individual
studies. Participant inclusion was mainly based on the pres-
ence of IC with a resting ankle-brachial index (ABI) <0.9 or a
reduction in ABI after exercise. Common exclusion criteria
included critical limb ischaemia, contra-indications to exer-
cise (e.g., unstable cardiac disease), and co-morbidities that
limited walking capacity. Only three studies presented
sample-size calculations.12,22,28
The components of the HEPs varied greatly between
studies and were generally poorly reported. All studies
included an exercise prescription, most commonly of
Table 1. Clinical trials comparing home-based exercise programmes (HEPs) with supervised exercise programmes (n ¼ 6).
Study (country),
design, quality
Sample Description of interventions Outcome measures, follow-up Main ﬁndings
Patterson et al.16
1997
(USA)
Randomised trial
Low quality
Total n ¼ 55
IC for >3 months;
age 50e75 years;
ABI <0.9 at rest
and 15 mmHg
drop in ankle pressure
with exercise; patients
without rest pain or
signiﬁcant co-morbidities
(arthritis, cardiac
ischaemia, etc.)
HEP: 12 weeks of prescribed
walking exercise (>3 
20e40-min walks per
week to “tolerance”),
weekly exercise logs
with weekly nurse
review, and weekly
lectures about risk
factors for atherosclerosis,
nutrition, exercise and
potential complications
of PAD
Supervised exercise: 12
weeks of supervised
aerobic exercise (3 
60-min sessions per week;
mixture of arm and leg
ergometry and treadmill
walking) and weekly
lectures as above
PWT and MWT on an
incremental treadmill
test
SF-36
Outcomes assessed at
baseline, intervention
end-point (12 weeks)
and at 6 months
HEP: 61% completed to follow-up. Improvements
in PWT, MWT and physical functioning and bodily
pain on the SF-36 (all p <.05)
Supervised exercise: 59% completed to follow-up.
Marked increases in PWT and MWT (>twofold
greater than HEP group). Signiﬁcant
improvements in physical functioning and bodily
pain on the SF-36 (all p <.05)
Conclusion: Improvements in walking capacity
were superior after supervised exercise; however,
a structured HEP may still provide beneﬁt
Regensteiner
et al.17
1997
(USA)
Randomised trial
Low quality
Total n ¼ 20
Disabling IC for >3 months;
ABI <0.94 at rest and
<0.73 after exercise;
ambulant patients
without critical
ischaemia, diabetes
or revascularisation
<12 months
HEP: 12 weeks of prescribed
walking exercise (>3 
35e50-min walks per week
[including rest periods] as
fast as possible to the point
of moderate leg pain) and
weekly phone contact to
assess compliance
Supervised exercise: 12
weeks of hospital-based
treadmill walking exercise
(3  35e50-min walks per
week [including rest periods]
as fast as possible to the
point of moderate leg pain)
PWT and MWT on an
incremental treadmill
test
WIQ
SF-20
Outcomes assessed at
baseline and intervention
end-point (12 weeks)
HEP: 100% study completion and exercise
adherence; no change in outcomes (ESWG for
MWD ¼ 0.08) except for a 13 percentage point
increase in ability to walk distances on the WIQ
Supervised exercise: 100% study completion and
exercise adherence. 150% and 137% increases in
PWT and MWT, respectively (ESWG for
MWD ¼ 2.63). Signiﬁcant improvements in all
WIQ sub-scale scores and the physical
functioning score of the SF-20 (all p <.05)
Conclusion: Supervised exercise was effective,
but the HEP was not (ESBG ¼ 2.0). The authors
proposed that the ineffectiveness of the HEP
might be owing to patients performing a lower
intensity of exercise; however, this was not
measured
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Table 1-continued
Study (country),
design, quality
Sample Description of interventions Outcome measures, follow-up Main ﬁndings
Savage et al.18
2001
(USA)
Randomised trial
Low quality
Total n ¼ 21
IC and age >50 years;
ABI 0.95 at rest;
patients without
signiﬁcant co-morbidities
(arthritis, unstable
cardiac disease,
cognitive impairment,
etc.) or revascularisation
within previous 3 months
HEP: 24 weeks of prescribed
walking exercise (>3 
15e40-min walking per
week [not including rest
periods] to the point of
intense leg pain) and monthly
telephone contact to provide
encouragement
Supervised exercise: 12 weeks
of hospital-based treadmill
walking exercise (3  15e40-min
walking per week [not including
rest periods] to the point of
intense leg pain) followed by
12 weeks of self-managed
exercise as described below
PWD and MWD on an
incremental treadmill test
SF-36
Outcomes assessed at
baseline, 3 months,
and 6 months
HEP: 100% study completion. PWD and MWD
were higher at 3 months (24% and 38%) and 6
months (44% and 34%), but only signiﬁcantly so
for MWD at 6 months (ESWG ¼ 0.69). There were
no marked changes in quality of life (p >.05)
Supervised exercise: 100% study completion.
PWD and MWD were signiﬁcantly (p <0.05)
increased at 3 months (89% and 60% [p ¼ .07])
and 6 months (106% and 42%; ESWG for
MWD ¼ 0.84), with no marked changes in quality
of life (p >.05)
Conclusion: Improvements in walking capacity
were superior after supervised exercise
(ESBG ¼ 0.14); however, a structured HEP may
still provide beneﬁt
Degischer et al.19
2002
(Switzerland)
Three-arm,
non-randomised,
longitudinal cohort
study
Low quality
Total n ¼ 69
(23 self-management,
26 supervised)
Stable IC for 3
months; patients
without signiﬁcant
orthopaedic, cardiac,
or pulmonary
co-morbidities
HEP: 3 months of prescribed
walking exercise (daily 60-min
walks to maximal claudication
pain [including rest periods]),
information at baseline
about PAD and atherosclerotic
risk, exercise logbooks and
weekly phone contact to
provide advice in relation to
any training-related problems.
Supervised exercise: 3 months
of supervised treadmill walking
exercise (3  60-min sessions
of intermittent walking at
60% maximum walking
capacity per week [including
rest periods])
Supervised exercise þ
clopidogrel: Not discussed
here as irrelevant
PWD and MWD on an
incremental treadmill
test
Outcomes assessed at
baseline, 3 months
(intervention end-point),
and 6 months
HEP: 91% study completion, unclear exercise
adherence. MWD was largely unchanged
(ESWG ¼ 0.03), whereas PWD was increased by
44% and 53% at 3 and 6 months respectively (p
<.05).
Supervised exercise: 73% study completion. All
but two patients completed >30/36 exercise
sessions. PWD and MWD were signiﬁcantly (p
<.05) increased at 3 months (164% and 82%) and
6 months (146% and 70%; ESWG ¼ 1.40)
Conclusion: Improvements in walking capacity
were superior after supervised exercise
(ESBG ¼ 1.43); however, a structured HEP may
still provide beneﬁt in motivated patients
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Table 1-continued
Study (country),
design, quality
Sample Description of interventions Outcome measures, follow-up Main ﬁndings
Fakhry et al.20
2011
(the Netherlands)
Non-randomised,
longitudinal cohort
study
Low quality
Total n ¼ 217
IC and age >18 years;
ABI <0.9 at rest
or >30% drop with
exercise; baseline
PWD <350 m; patients
without signiﬁcant
co-morbidities
(lifestyle-limiting
cardiac disease, etc.)
HEP: 24 weeks of prescribed
walking exercise (at least
one 30-min walk daily to
near-maximal leg pain,
including recovery periods
of slower walking), feedback
on progress at weeks 2, 8,
16, and 24 (from self-reported
compliance and objective
walking test data), goal-setting,
discussion of barriers to
exercise, and education about
treatment of IC and potential
beneﬁts of exercise, followed
by advice to maintain exercise
in their daily routine through
weeks 24e48
Supervised exercise: 24 weeks
of supervised treadmill walking
exercise (2  30 mins walking
per week to near-maximum
leg pain, including recovery
periods of slower walking)
followed by 24 weeks of unsupervised
exercisedinstruction to
“walk on a daily basis”
PWD and MWD on a
constant-load treadmill test
EQ-5D, SF-36 (generic,
health-related quality
of life)
VascuQol (disease-speciﬁc
quality of life)
Outcomes assessed at
baseline, 6 months,
and 12 months
HEP: 67% study completion. PWD and MWD
were increased at 6 and 12 months (p<.05; ESWG
for MWD ¼ 1.91). Quality of life was generally
improved at 6 and 12 months, but to a lesser
extent than in the supervised exercise group
Supervised exercise: Compliance data not
reported. Marked increases in PWD and MWD
(ESWG for MWD ¼ 11.14). Signiﬁcant
improvements in scores on VascuQol, SF-36
(physical functioning, bodily pain, general health)
and EQ-5D. (all p <.05)
Conclusion: Improvements in walking capacity
and quality of life were superior after supervised
exercise (ESBG for MWD ¼ 5.42); however, a
structured HEP may still provide beneﬁt
Gardner et al.9
2011
(USA)
Three-arm
randomised
controlled trial
(including usual
care)
Moderate quality
Total n ¼ 119
(40 self-management,
40 supervised)
IC with ABI 0.90
at rest and 0.73
after exercise; patients
without active cancer
or renal or liver disease
HEP: 12 weeks of prescribed
walking exercise (3 
20e45 mins walking per
week [not including rest
periods] to near-maximum
leg pain) and pedometer
and exercise logbook use
with face-to-face feedback
on data and discussion of
barriers to exercise at
weeks 1, 2, 4, 6, 8, 10,
and 12.
PWT and MWT on an
incremental treadmill
test
Pedometer
(ambulatory activity)
WIQ
SF-36
Outcomes assessed at
HEP: 72.5% study completion, 82.5% exercise
adherence. 65% and 31% increases in PWT and
MWT (ESWG ¼ 0.44) respectively. Increased
walking cadence, but no signiﬁcant change in
total daily steps. Improvements in all WIQ sub-
scale scores and the physical-functioning score of
the SF-36
Supervised exercise: 82.5% study completion,
84.8% exercise adherence. 84% and 66%
increases in PWT and MWT (ESWG ¼ 1.27)
respectively (p >.05 vs. HEP). No signiﬁcant
changes in ambulatory activity. Signiﬁcant
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21,23e25,29 Seven programmes promoted 3 walking bouts
per week,9,12,16e18,22,23,29 whereas nine promoted daily
walking.8,19e21,25e28,30 Duration of walking sessions ranged
from 10 minutes8,27,30 to 60 minutes,19,21,28 but was most
commonly w30e40 minutes.9,12,16e18,20,23,25,26,29 Twelve
interventions included follow-up with a healthcare profes-
sional, either face-to-face8,9,16,20,21,26,27,29 or by tele-
phone;8,12,17e19,22,23,27,28 however, the frequency of follow-
up varied, ranging from weekly16,19,28 to bi-monthly.29
Seven programmes included education about
PAD.12,16,19,20,22e24,29 Ten programmes prompted self-
monitoring with logbooks8,9,16,19,25,27e30 or pedome-
ters.9,21,22 Only three programmes reported using exercise
counselling based on a theoretical model.12,22,23,25 Four
programmes included goal-setting,12,20,22,23,29 whereas
eight included barrier identiﬁcation/problem-solv-
ing.8,9,12,19,20,22e24,27
Walking capacity was objectively assessed in all but one
study, which assessed changes in PWD subjectively.12,23
Eleven studies used an incremental treadmill walking
test,9,16e19,22,24,25,27e29 two used a constant-load treadmill
test,20,21 two used both of these approaches,8,30 and one
used a self-paced corridor-walking test.26 Walking behav-
iour was objectively assessed in only two studies.9,12,23 Two
studies reported monitoring changes in psychological con-
structs that might mediate behaviour change (e.g., walking
self-efﬁcacy),12,22,23 but neither presented these data. Five
studies included a patient-reported measure of functional
status,9,12,17,22,23,25 typically the Walking Impairment
Questionnaire (WIQ).31 Nine studies assessed quality of
life,9,12,16e18,20,22,23,28,30 typically using the Medical Out-
comes Study SF-36 instrument (SF-36).32 Cardiovascular risk
factors were rarely reported, with only three studies
describing changes in blood pressure.8,27,28 No study re-
ported adverse events. Follow-up ranged from 3
months9,17,26,28 to 24 months.23 Intention-to-treat analysis
was reported in three studies.9,12,22,23 Trial heterogeneity
prevented meta-analysis. Hence, a qualitative synthesis of
“best evidence” was conducted.HEPs versus supervised exercise programmes
Four randomised trials9,16e18 and two non-randomised
prospective studies19,20 compared HEPs with supervised
exercise training (Table 1). One study was of moderate
methodological quality9 and ﬁve were of low quality.16e20
Study completion rates ranged from 61% to 100% for
HEPs and from 59% to 100% for supervised exercise
training. Exercise compliance was only clearly reported in
two studies;9,17 both groups achieved 100% compliance in
the study of Regensteiner et al.,17 whereas compliance was
82.5% and 84.8% for HEP and supervised training, respec-
tively, in the study of Gardner et al.9 The moderate-quality
study of Gardner et al.9 was a three-arm RCT of a 12-week
HEP versus supervised exercise training versus usual care
(n ¼ 119). The HEP group was instructed to perform three,
20e45-minute sessions of intermittent walking to near-
Table 2. Clinical trials comparing home-based exercise programmes (HEPs) with usual care/observation control (n ¼ 5).
Study (country), design, quality Sample Description of interventions Outcome measures, follow-up Main ﬁndings
Larsen and Lassen21
1966
(Denmark)
Randomised controlled trial
Low quality
Total n ¼ 14
Typical IC with no co-morbidity that
limited normal physical activity
HEP: 6 months of prescribed
walking exercise (60-min of
intermittent walking to near-
maximal leg pain daily) and
pedometer use with weekly (month
1) or monthly (months 2e4)
discussion of compliance
Control: Placebo (lactose) tablets,
twice daily
PWD and MWD on a constant-load
treadmill test
Outcomes assessed at baseline and
monthly until intervention end-
point (6 months)
HEP: 100% study completion. At 6
months, PWD and MWD were
increased by 106% and 183%
respectively (p <.05). The
magnitude of beneﬁt varied greatly
between individuals
Usual care: 100% study completion.
Non-signiﬁcant (p >.2) decreases in
PWD and MWD of 11% and 6%
respectively
Conclusion: The HEP improved
walking capacity relative to placebo
control
Manfredini et al.8
2008
(Italy)
Non-randomised controlled trial
Low quality
Total n ¼ 143
Stable IC and PAD based on clinical
examination and duplex scanning;
patients with no contraindications
to exercise and who abstained from
smoking
HEP: 24 weeks of prescribed
walking exercise (6  twice daily
interval walking sessions of 10 min
each at maximal asymptomatic
speed [via metronome]), exercise
logbooks with family member/
caregiver support, option for
patient to telephone the
rehabilitation team as needed and
monthly “check-ups” at assessment
visits
Control: Basic advice to walk 20
e30 min/day for 6 days/week at a
self-selected walking speed up to
the onset of leg pain. Family
members were asked to monitor
that the exercise was being done
correctly
PWD and MWD on a constant-load
treadmill test
Pain threshold and maximal speeds
on an incremental treadmill test
Systolic and diastolic blood pressure
Outcomes assessed at baseline and
after 1, 2, 3, 4, and 6 months of
follow-up
HEP: 89% study completion,
exercise adherence unclear. At 6
months, PWD, MWD, pain
threshold speed and maximal speed
were increased by 59%, 62%
(ESWG ¼ 1.30), 43% and 24%
respectively (all p <.01 vs. control).
Systolic and diastolic pressures
decreased by 7 and 4 mmHg
respectively (p <.05)
Usual care: 87% study completion,
exercise adherence unclear. At 6
months, PWD, MWD, pain
threshold speed and maximal speed
were increased by 30%, 32%
(ESWG ¼ 0.59), 27% and 11%
respectively (all p <.001 vs.
baseline) Systolic pressure
decreased by 5 mmHg (p <.05), but
diastolic remained largely
unchanged (p >.05)
Conclusion: The HEP, which involved
instruction for regular pain-free
walking, improved walking capacity
relative to usual care (ESBG ¼ 0.57)
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Table 2-continued
Study (country), design, quality Sample Description of interventions Outcome measures, follow-up Main ﬁndings
Collins et al.22
2011
(USA)
Randomised controlled trial
Low quality
Total n ¼ 145
IC or atypical leg symptoms with ABI
<0.90 or toe-brachial index 0.70
at rest; age >40 years; type I or II
diabetes mellitus; patients without
critical ischaemia or signiﬁcant co-
morbidities (e.g., arthritis, unstable
cardiac disease, severe
hypertension)
HEP: 6 months of prescribed
walking exercise (>4  50 mins
walking per week, of which one
session was supervised), patient-
centred behavioural counselling
based on the patient’s current stage
of change, goal-setting, and barrier
identiﬁcation (all at baseline),
pedometer use, educational video
about PAD, and biweekly phone
contact to discuss progress
Control: 6 months of biweekly
phone calls to discuss risk factor
management, including physical (in)
activity where applicable, and
educational video about PAD
PWD and MWD on an incremental
treadmill test
WIQ (self-reported functional
status)
SF-36 (health-related quality of life)
Outcomes assessed at baseline, 3
months and 6 months
HEP: 85% study completion. At 6
months, PWD and MWD were
increased by 66.7 m and 24.5 m (p
>.05 vs. control; ESWG for
MWD ¼ 0.10). There were some
small improvements in self-reported
functional status and quality of life,
but changes were only greater than
control for WIQ-distance and
mental health on SF-36
Control: 89% study completion. At 6
months, PWD and MWD were
increased by 52.3 m and 39.2 m
(ESWG for MWD ¼ 0.17). There were
no marked improvements in
functional status or quality of life
Conclusion: The HEP did not
improve walking capacity and had
limited beneﬁt on patient-reported
functional status and quality of life
vs. control (ESBG ¼ 0.06, favouring
control)
Gardner et al.9
2011
(USA)
Three-arm randomised controlled
trial (including usual care)
Moderate quality
Total n ¼ 119 (40 self-management,
39 usual care)
IC with ABI 0.90 at rest and 0.73
after exercise; patients without
active cancer or renal or liver
disease
HEP: See Table 1
Usual care control: Basic advice to
walk more
PWT and MWT on an incremental
treadmill test
Pedometer (ambulatory activity)
WIQ, SF-36
Outcomes assessed at baseline and
intervention end-point (12 weeks)
HEP: 72.5% study completion,
82.5% exercise adherence. 65% and
31% increases in PWT and MWT,
respectively (p <.01 vs. control).
Increased walking cadence, but no
signiﬁcant change in total daily
steps. Signiﬁcant improvements in
all WIQ sub-scale scores and the
physical functioning score of the SF-
36
Usual care: 76.9% study completion.
No marked changes in walking
capacity (ESWG for MWD ¼ 0.05)
or patient-reported outcomes (all p
>.05).
Continued
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Table 2-continued
Study (country), design, quality Sample Description of interventions Outcome measures, follow-up Main ﬁndings
Conclusion: The HEP was clearly
superior to usual care for improving
walking capacity (ESBG ¼ 0.54) and
quality of life
Cunningham et al.12,23
2012/2013
(UK)
Randomised controlled trial
Moderate quality
Total n ¼ 58
IC due to PAD conﬁrmed by ABI
<0.90 after exercise and duplex and
magnetic resonance imaging;
patients with contraindications to
exercise
HEP: 2  1-h meetings with a
psychologist in the patient’s home;
patient-centred education about
PAD and walking based using
motivational interviewing and the
Common-Sense Model of Self-
regulation of Health and Illness;
goal-setting based on the
recommendation to walk to near-
maximal leg pain for >30 min, three
times per week; strategies for
overcoming barriers; telephone call
at 6 and 12 weeks to discuss
progress
Usual care control: Basic advice to
walk more; information sheet on
PAD; consultation with a vascular
surgeon
Pedometer (daily steps)
Perceived PWD
ICQ (disease-speciﬁc quality of life)
WHOQOL-BREF (general quality of
life)
Outcomes assessed at baseline,
after 4 months of follow-up [12],
and after 12 and 24 months of
follow-up [33]
HEP: At 4 months [12], there were
signiﬁcant improvements in daily
steps, perceived PWD, and general
quality of life vs. control, with 97%
study completion across both
groups. At 24 months [33], there
were signiﬁcant improvements in
daily steps vs. control and in
perceived PWD and quality of life
vs. baseline (88% study completion
across both groups). The change in
walking behaviour may have been
moderated by whether or not
participants had a revascularisation
procedure during follow-up. Rates
of revascularisation were lower in
the HEP group
Usual care: No changes from
baseline in any outcome at 4
months, but improved perceived
PWD and quality of life at 24
months
Conclusion: The brief HEP was
associated with improved walking
behaviour and a reduced rate of
revascularisation relative to usual
care.
Note. ABI ¼ ankle-brachial index; ESBG ¼ between-group effect size; ESWG ¼ within-group effect size; IC ¼ intermittent claudication; ICQ ¼ Intermittent Claudication Questionnaire;
MWD ¼ maximum walking distance; MWT ¼ maximum walking time; PAD ¼ peripheral arterial disease; PWD ¼ pain-free walking distance; PWT ¼ pain-free walking time; SF-
36 ¼ Medical Outcomes Study Short-Form 36 instrument; WHOQOL-BREF ¼ World Health Organization Quality of Life Questionnaire; WIQ ¼ Walking Impairment Questionnaire.
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Table 3. Clinical trials evaluating home-based exercise programmes (HEPs) only (n ¼ 7).
Study (country),
design, quality
Sample Description of
interventions
Outcome measures,a
follow-up
Main ﬁndings
Jonason et al.24
1981
(Sweden)
Single-group
prospective study
Low quality
n ¼ 15
IC and ankle pressure
>15 mmHg lower than
arm pressure; patients
without angina
pectoris
HEP: 3 months of
prescribed “gymnastic
training” and walking
(to be performed
repeatedly until they
produced pronounced
pain) and information
at baseline about PAD,
followed by 3 months
of supervised exercise
training
PWD and MWD on an
incremental treadmill
test
Outcomes assessed at
baseline, 3 months,
and 6 months
HEP: 100% completion
at 3 months. At 3
months, PWD and
MWD were increased
by 67% and 61%
respectively (p <.01).
The magnitude of
beneﬁt was similar to
that observed with
supervised exercise
training in a previous
study by this group
Conclusion: The HEP
improved walking
capacity; however, the
intervention was
poorly deﬁned
Wullink et al.25
2001
(the Netherlands)
Single-group
prospective study
Low quality
n ¼ 31
IC with ABI <0.90 at
rest and <0.80 after
exercise; patients
without critical
ischaemia, planned
revascularisation, or
co-morbidities that
limit walking
HEP: 24 weeks of
prescribed walking
exercise (9  30-min
walking bouts per
week to near-maximal
leg pain), 10-min
exercise counselling
sessions every 3 weeks
based on the Health
Counselling Model,
exercise diaries,
discussion of exercise
barriers and coping
strategies
PWD and MWD on an
incremental treadmill
test
WIQ
Outcomes assessed at
baseline and after 6,
12, and 24 weeks of
follow-up
HEP: 77% study
completion. Patients
completed a mean of
7.4 exercise bouts per
week. At 24 weeks,
PWD was signiﬁcantly
increased by 20% (p
<.05), whereas MWD
was not (þ11%, p
>.05). The WIQ sub-
scales improved by 2
e6 points; however,
changes were non-
signiﬁcant
Conclusion: Overall,
the HEP appeared to
evoke a small
improvement in
walking capacity
Spronk et al.26
2003
(the Netherlands)
Single-group
prospective study
Low quality
n ¼ 104
Stable IC for >3
months with ABI
<0.90 at rest or >30%
drop after exercise;
patients without
critical ischaemia or
co-morbidities that
limit walking
HEP: 16 weeks of
prescribed walking
exercise (twice daily
w35-min sessions of
intermittent walking to
the onset of
claudication pain),
encouragement and
advice from a vascular
nurse at weeks 2, 8,
and 16
PWD on a “corridor
walking test”
Outcomes assessed at
baseline, 8 weeks, and
12 weeks
HEP: 71% study
completion. At 24
weeks, PWD was
increased by 180% (p
<.05)
Conclusion: The HEP
improved PWD;
however, the walking
capacity protocol was
not clearly reported
Manfredini et al.27
2004
(Italy)
Single-group
prospective study
n ¼ 29
Stable IC
HEP: 4 months of
prescribed daily
walking sessions at a
speed 20e30% below
pain threshold speed,
exercise diary for
compliance
Pain-threshold and
maximal speeds on an
incremental treadmill
test
Systolic and diastolic
blood pressure
HEP: Pain threshold
and maximal speeds
were increased by 50%
and 21% respectively.
Resting systolic and
diastolic blood
pressures decreased
Continued
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Table 3-continued
Study (country),
design, quality
Sample Description of
interventions
Outcome measures,a
follow-up
Main ﬁndings
Low quality Outcomes assessed at
baseline and 4 months
by 4 and 5 mmHg
respectively (all p
<.05)
Conclusion: The HEP
improved walking
capacity (ESWG ¼ 0.54)
and systemic blood
pressure
Roberts et al.28
2008
(UK)
Single-group
prospective study
Low quality
n ¼ 47
Age 40e85 years with
stable IC for >3
months; ABI <0.90 at
rest or duplex imaging
showing signiﬁcant
lower limb arterial
stenosis; patients
without
contraindications to
exercise
HEP: 12 weeks of
prescribed walking
exercise (daily 1-h
walks, including rest
periods), weekly
phone call to discuss
progress, exercise
diary
MWD on an
incremental treadmill
test
VascuQol (disease-
speciﬁc quality of life)
Systolic and diastolic
blood pressure
Outcomes assessed at
baseline and 12 weeks
HEP: Study completion
rate unclear. Median
self-reported exercise
compliance was 5 h
per week. MWD
increased by 76% and
exercise compliance
was correlated with
improvement in MWD.
There was a trend
(p ¼ .07) for a
reduction in resting
systolic blood
pressure, with little
change in diastolic
pressure (p ¼ .32).
Signiﬁcant
improvements in all
quality of life domains
except social
functioning
Conclusion: The HEP
improved walking
capacity and quality of
life
Mouser et al.29
2009
(USA)
Single-group
retrospective study of
routine care
Low quality
n ¼ 120
IC with ABI <0.90 at
rest or after exercise;
patients without
critical ischaemia or
co-morbidities that
limit walking
HEP: 6 months of
prescribed walking
exercise (3
e5  >30 min of
intermittent walking
per week [not
including rest periods]
to near-maximal leg
pain), goal-setting,
exercise diary,
education at baseline
on PAD and lifestyle,
encouragement and
advice from an
exercise physiologist
every 2 months
PWD and MWD on an
incremental treadmill
test
Outcomes assessed at
baseline and 6 months
HEP: 34% study
completion. PWD and
MWD increased by
86% and 20%
respectively (p <.01)
Conclusions: The HEP
improved walking
capacity
(ESWG ¼ 0.28), but to a
lesser extent than
comparable
programmes of
supervised exercise
training
Malagoni et al.30
2011
(Italy)
Single-group
n ¼ 250
Stable IC for >6
months without
HEP: Prescribed
walking exercise
(6  two daily interval
walking sessions of
10 min each at
PWD and MWD on a
constant-load
treadmill test
Pain threshold speed
HEP: 98% study
completion. The mean
duration of
rehabilitation was 12
months (range 9e17).
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Table 3-continued
Study (country),
design, quality
Sample Description of
interventions
Outcome measures,a
follow-up
Main ﬁndings
retrospective study
Low quality
contraindications to
exercise
maximal asymptomatic
speed [via
metronome]), exercise
logbooks with family
member/caregiver
support, option for
patient to telephone
the rehabilitation team
as needed and
monthly “check-ups”
at assessment visits.
on an incremental
treadmill test
SF-36
Outcomes assessed at
admission and
discharge
Compliance was
generally good (on an
arbitrary scale). PWD
and MWD increased
by 46% and 44%
respectively (p <.01).
All SF-36 domains
scores were
signiﬁcantly improved
at discharge (p <.01)
Conclusions: The low-
cost HEP improved
walking capacity
(ESWG ¼ 0.78) and
quality of life
Note. ABI ¼ ankle-brachial index; ESWG ¼ within-group effect size; IC ¼ intermittent claudication; MWD ¼ maximum walking distance;
PAD ¼ peripheral arterial disease; PWD ¼ pain-free walking distance; SF-36 ¼ Medical Outcomes Study Short-Form 36 instrument;
VascuQol ¼ Vascular Quality of Life Questionnaire; WIQ ¼ Walking Impairment Questionnaire.
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dometers and exercise diaries to quantify exercise per-
formed. Brief meetings were held with an exercise
physiologist biweekly to provide feedback on walking data
and to discuss any problems. Rates of study completion and
exercise compliance were similar between the home-based
and supervised exercise groups (all >72.5%). Improvements
in PWT and MWT were reported with HEP (65% and 31%
respectively) and supervised training (84% and 66%
respectively), which did not differ statistically between
groups (p >.05; ESBG ¼ 0.40 favouring supervised exercise).
Additionally, patient-reported functional status (WIQ) and
physical functioning (SF-36) improved in both groups. The
other ﬁve studies all concluded that supervised pro-
grammes evoked superior improvements in walking capac-
ity (ESBG ¼ 0.14e5.42) and quality of life than HEPs,16e20
with two showing little change from baseline with
HEP.17,19 No studies investigated changes in cardiovascular
disease risk markers.HEPs versus usual care/observation control
Four RCTs9,12,21e23 and one non-RCT8 compared HEPs with
usual care or observation control (Table 2). Two studies
were of moderate methodological quality,9,12,23 and three
were of low quality.8,21,22 Study completion rates ranged
from 72.5% to 100.0% for HEPs and from 76.9% to 100.0%
for usual care/observation. Exercise compliance was only
reported by Gardner et al. (described above).9 Here, the
HEP was clearly superior to usual care for improving walking
capacity (ESBG ¼ 0.54) and quality of life. Cunningham
et al.12,23 conducted a RCT of a HEP versus usual care
(n ¼ 58). The HEP comprised a brief psychological inter-
vention based on the Common-Sense Model of Self-
regulation of Health and Illness,33 which was delivered by
a psychologist in two 1-hour sessions in participants’homes. Other intervention components were goal-setting
based on the recommendation to walk to near-maximal
leg pain for >30 minutes, three times per week, develop-
ment of action plans and coping strategies, and follow-up
telephone contact with the psychologist at 6 and 12
weeks. At 4 months of follow-up, daily steps increased in
HEP versus usual care (mean difference of 1,576 steps),
accompanied by a perceived increase in PWD.12 At 24
months, the HEP group showed a sustained increase in daily
walking accompanied by a reduced rate of revascularisa-
tion.23 Collins et al.22 randomised 145 patients with symp-
tomatic PAD and diabetes mellitus to HEP or attention
control. The HEP group attended weekly centre-based
walking sessions and were prescribed an additional three
walks per week at home (50 minutes per session). Other
intervention components included patient-centred coun-
selling based on the patient’s current stage of behaviour
change, goal-setting and barrier identiﬁcation, pedometer
use, an educational video on PAD, and biweekly telephone
contact to discuss progress. At follow-up, there was little
change within or between groups for PWD, MWD
(ESBG ¼ 0.06 favouring control), or self-reported functional
status and quality of life. The other two studies both
concluded that participation in a HEP evoked superior im-
provements in walking capacity8,21 and resting blood pres-
sure8 than usual care/observation.Single-arm trials of HEPs only
Seven studies (ﬁve prospective, two retrospective) evalu-
ated the effects of HEPs with a single-group design
(Table 3), all of which were of low quality.24e30 Study
completion was >70% in four studies,24e26,30 but only 34%
in the study of Mouser et al.,29 which was a retrospective
study of routine clinical care. All studies reported im-
provements from baseline in walking capacity, although the
702 W. Al-Jundi et al.effect size varied greatly, with improvements in PWD and
MWD ranging from 20% to 180% and from 11% to 76%
respectively.24e30 Some studies also reported data indi-
cating improvements in quality of life28,30 and resting blood
pressure.27,28 Exercise compliance was unclear in most
studies.DISCUSSION
The 17 included studies evaluated a range of HEPs promoting
self-managed walking in individuals with IC. The studies were
mostly of low methodological quality. There was “low-level”
evidence that HEPs can improve walking capacity and quality
of life in patients with IC when compared with baseline or in
comparison to usual care (i.e., basic advice to walk more) or
observation only. In addition, improvements with HEPs may
be inferior to those resulting from supervised exercise pro-
grammes. Little is currently known about the effect of HEPs
on cardiovascular disease risk.
There have been previous systematic reviews and meta-
analyses of supervised versus unsupervised exercise
training in patients with PAD;34,35 however, direct compar-
isons cannot be drawn with our review because the studies
reviewed previously mostly involved basic advice to walk
more as the unsupervised exercise intervention. This raises
an important point about appropriate terminology; “unsu-
pervised exercise training” is vague as this could be pro-
moted by basic advice to walk more (what we called “usual
care”) through to complex, multi-component behaviour
change programmes (what we call structured HEPs), ex-
tremes that are likely to vary somewhat in terms of clinical
and cost effectiveness. Thus, it seems important for the
development of a coherent evidence base and disease-
management guidelines that the effects of these different
approaches are reviewed independentlydsomething which
is not the case in the American College of Cardiology/
American Heart Association guidelines.5 Along these lines,
Makris et al.10 recently attempted to synthesise the evi-
dence on HEPs in patients with PAD. Unfortunately, this
review had several limitations: the database search was
limited to 1990 onwards, there was no formal assessment
of the quality of included studies, relevant articles were not
included,17e19,30 and trials of supervised exercise training in
the community setting were included, which is clearly not
what we consider a HEP. Hence, we believed there was
need for a more comprehensive and focussed synthesis of
the literature. Despite the shortcomings of the previous
review, the conclusions are much the same as ours: there is
some preliminary evidence that HEPs are useful for
improving walking capacity and quality of life in patients
with IC, but further, well-designed studies are required. We
are aware of two ongoing studies in this area: one in the
USA36 and one in the UK (Clinicaltrials.gov: NCT01776710).
Fifteen of the 17 included trials were rated as low quality
owing to substantial ﬂaws in their design. Common limita-
tions included lack of description of randomisation proce-
dure; non-blinding of outcome assessors; unjustiﬁed and
small sample sizes; limited generalisability of the results(because most studies recruited participants from a single
centre with strict eligibility criteria); uncertainty about
whether intervention components were delivered as
intended; lack of an intention-to-treat analysis protocol; and
lack of long-term follow-up.
The HEPs varied greatly, from basic exercise prescription
and use of exercise diaries to programmes combining
theory-based exercise counselling and several behaviour
change techniques; however, in many cases, intervention
components were poorly described and unjustiﬁed. Never-
theless, successful HEPs typically included self-monitoring
(e.g., the patient keeping a logbook of their walking
behaviour), goal-setting, and identiﬁcation of barriers to
walking and solutions to overcoming them: behaviour
change techniques that have shown to be effective in
supporting physical activity behaviour change in a previous
meta-regression study.37 Three points are worthy of further
discussion in relation to intervention design. Firstly, it was
interesting to note that most interventions promoted
intermittent walking to near-maximal claudication pain.
While consistent with current recommendations,2,5 such a
prescription appears behaviourally counterintuitive and
may lead to low adoption and adherence rates. A recent
review by Parmenter et al.38 highlighted preliminary evi-
dence that clinically meaningful improvements in walking
capacity can be achieved through lower-intensity or pain-
free walking exercise. Therefore, the prescription of pain-
free walking exercise may be more appropriate, at least
as a starting point, for promoting long-term behaviour
change, particularly in individuals who indicate that they
might be intolerant of painful walking exercise. It is also
likely that accumulation of small changes in walking
behaviour is more acceptable than immediate large changes
and that long-term behaviour change is more likely to occur
when patients are involved in the setting of goals, action
plans, and coping strategies.39 Although other modes of
exercise (e.g., arm-cranking, cycling) could be useful for
improving walking capacity in patients with IC,38 walking
remains the preferred mode in home-based exercise pre-
scriptions because it is a common, acceptable, cheap form
of physical activity that requires little planning and has
demonstrable cardiovascular beneﬁts,40 although the latter
has yet to be clearly demonstrated in patients with IC.
Secondly, very few of the included studies described
theoretical models upon which the HEPs were based. In the
absence of theoretical underpinning, intervention design is
derived from implicit theories that may omit psychological
processes central to behaviour change and so fail to opti-
mise effectiveness.41 The generalisability of such in-
terventions is also limited if change mechanisms are poorly
understood.41 A theory is a system of ideas, conﬁrmed by
observation or experiment, which explains a group of facts
or phenomena. In the context of this review, a relevant
theory would provide a clear account of the psychological
processes accounting for the change (or not) in walking
behaviour elicited by a HEP. French et al.42 recently
described several important steps in the systematic devel-
opment of interventions to promote self-managed physical
Table 4. Quality assessment proﬁles.
Quality assessment Quality
Study Design Study limitations Inconsistency Indirectness Imprecision Other considerations
Patterson et al.16 Randomised trial Serious None None Serious Data were not reported for
exercise adherence. Effects sizes
not calculable
Low
Regensteiner et al.17 Randomised trial Serious None None Serious None Low
Savage et al.18 Randomised trial Serious None None Serious Data were not reported for
exercise adherence
Low
Degischer et al.19 Non-randomised, cohort study Serious None None Very serious None Low
Fakhry et al.20 Non-randomised, cohort study Very serious None None None Data were not reported for
exercise adherence
Low
Gardner et al.9 Randomised controlled trial None None None Serious None Moderate
Larsen and Lassen21 Randomised controlled trial Very serious None None Very serious Effect sizes not calculable Low
Manfredini et al.8 Non-randomised controlled trial Serious None None Serious None Low
Collins et al.22 Randomised controlled trial Very serious None None None Data were not reported for
exercise adherence
Low
Cunningham et al.12,23 Randomised controlled trial None None None Serious Data were not reported for
exercise adherence
Moderate
Jonason et al.24 Single-group prospective study Very serious None None Very serious Effect size not calculable Low
Wullink et al.25 Single-group prospective study Very serious None None Very serious Effect size not calculable Low
Spronk et al.26 Single-group prospective study Very serious None None Serious Exercise adherence data were
unclear
Low
Manfredini et al.27 Single-group prospective study Very serious None None Very serious Rates of study completion and
exercise adherence were unclear
Low
Roberts et al.28 Single-group prospective study Very serious None None Serious Effect size not calculable Low
Mouser et al.29 Single-group retrospective study Very serious None None Very serious Data were not reported for
exercise adherence
Low
Malagoni et al.30 Single-group retrospective study Very serious None None Very serious None Low
Note. None ¼ no serious issues with the evidence; Serious ¼ issues that are serious enough to downgrade the quality rating by one level; Very serious ¼ issues that are serious enough to
downgrade the quality rating by two levels.
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704 W. Al-Jundi et al.activity: (i) identiﬁcation of a relevant theoretical model (or
models) on which to base the intervention; (ii) identiﬁcation
of target psychological constructs within the model, and the
determinants of these constructs; (iii) identiﬁcation and
development of behaviour change techniques (e.g., devel-
opment of walking action plans, identiﬁcation of potential
barriers and coping strategies, self-monitoring of walking
activity) and intervention strategies most effective in
changing these constructs; and (iv) reﬁning of speciﬁc
strategies to change behaviour, including pilot work to
optimise the acceptability and efﬁcacy of the resultant draft
intervention. This has implications in the selection of out-
comes measures, which is discussed further below. It also
highlights the importance for clearly describing in-
terventions such that they can be replicated by others and
for helping to understand why an intervention works.
Although this may seem obvious, few of the studies
included in this review provided a sufﬁcient description of
intervention procedures to allow replication. We recom-
mend that in future reports of HEPs, behaviour change
techniques are clearly reported, perhaps using the classiﬁ-
cation system of Michie et al.43
Thirdly, during intervention design, it is important to
consider both the practicality and acceptability of what is
being proposed. While evidence from other reviews sug-
gests that higher-intensity interventions (i.e., greater pa-
tientepractitioner contact, more behaviour change
techniques) may be more effective in evoking increased
physical activity,44,45 a balance needs to be struck between
intensity, complexity, and what is deliverable in the current
healthcare climate. Ultimately, if an intervention is not
pragmatic, then the results of associated clinical trials are
unlikely to be transferable to everyday practice. Many of
the interventions that we identiﬁed in this review are not
what we consider to be pragmatic. For example, individual
face-to-face counselling by a psychologist in patients’
homes, as used in the study of Cunningham et al.,12 is
unlikely deliverable across a tax-funded healthcare system.
Neither are interventions that require frequent (e.g.,
weekly) interaction with a healthcare practitioner over a
prolonged period.9,16,17,19,22,28 Patients and individuals with
knowledge of healthcare commissioning should ideally be
actively involved in the design process (as well as evaluation
and dissemination) to help optimise the practicality, rele-
vance, and acceptability of the intervention to individuals
with IC.
Choice of outcome measures is also critically important.
It can be argued that if interventions are designed to
change behaviour in order to improve health, then health
outcome should be the index of success. In the context of
an exercise intervention designed to improve walking ca-
pacity in patients with IC then, perhaps, increased PWD/
MWD rather than increased walking activity should be the
critical outcome. Indeed, objectively-measured PWD and
MWD are often considered the primary outcomes of in-
terest in clinical trials of IC.46 This approach is limited when
evaluating behaviour change interventions, however,
because factors other than the target behaviour (i.e.,walking in this case) affect health status. Multiple lifestyle
characteristics, including a range of behaviours and
contextual factors, from socio-economic status to disease
prevalence,41 may moderate the effect of walking behav-
iour on a speciﬁed health outcome. Therefore, it appears
important to include accurate and reliable measures of
walking behaviour (e.g., daily steps using a pedometer or
accelerometer) alongside measures of walking capacity
when designing trials to evaluate HEPs. Only two of the 17
included studies did this.9,12 In addition, many studies failed
to assess treatment efﬁcacy from the patient perspective.
Several questionnaires exist for assessing functional status
and/or generic and disease-speciﬁc quality of life in patients
with PAD, with the WIQ and SF-36 most commonly used in
clinical trials of IC.46 We recommend that such measures
are included alongside measures of walking behaviour and
capacity in future evaluations of HEPs. Comprehensive
evaluations will also require detailed assessments of exer-
cise adherence, predicted psychological mediators of
behaviour change, measures of cardiovascular disease risk,
practicality and acceptability, treatment ﬁdelity, and costs.
Our conclusions are limited owing to the small number of
studies of mostly low quality. Additionally, we recognise
several limitations in the methodology of the review itself,
and the completeness of the retrieved literature. Firstly, we
were not able to rule out some degree of selection bias
from the literature search, given that the search strategy
principally encompassed the cited literature (English lan-
guage only), despite the extended range of terms that were
used to capture the relevant literature. Secondly, we were
unable to exclude publication bias as there may be negative
trials that are unpublished. Thirdly, reference bias is a
further possible confounder, as our search strategy included
searching of reference lists within the relevant articles for
other possible articles missed in our electronic searches.CONCLUSIONS
We provide the following cautious recommendation: clini-
cians should consider using HEPs to promote walking in
patients with IC, as opposed to basic “go home and walk”
advice, when supervised training is unavailable or imprac-
tical. This recommendation is based on several factors,
including “low-level” evidence supporting the efﬁcacy of
HEPs; basic advice has limited efﬁcacy; HEPs are probably
cheap, safe, and acceptable to patients; and HEPs appear
effective for improving a range of behavioural and health
outcomes in patients undergoing cardiac rehabilitation.47
More robust trials are needed to build the evidence base
for HEPs in individuals with IC. Speciﬁcally, there is need for
research to identify which theoretical models are most
relevant for promoting walking in patients with IC and
which psychological constructs to target within these
models. We also need to identify and develop change
techniques and intervention delivery strategies most
effective in changing these constructs. Ideally, this should
involve experimental studies evaluating the effectiveness of
theory-driven behaviour change techniques separately and
European Journal of Vascular and Endovascular Surgery Volume 46 Issue 6 p. 690e706 December/2013 705in combination with appropriate measures of predicted
psychological mediators and walking behaviour. Speciﬁc
strategies to promote walking will then need to be reﬁned
through pilot work to optimise the practicality and
acceptability of the resultant draft intervention before
progressing to adequately-powered, methodologically-
sound, RCTs exploring long-term clinical and cost
effectiveness.
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